We describe a patient with acute promyelocytic leukemia (APL) achieved complete remission after 1 month of therapy. Cytogwho was successfully induced into remission with all-trans retienetic studies showed a normal karyotype. Maintenance thernoic acid (ATRA) and idarubicin, but developed myelodysplasapy was started with two cycles of idarubicin at 12 mg/m 2 /day tic syndrome (MDS) with monosomy 7 shortly after conclusion month. This sequence (three POMP followed by one idarubicin) was repeated three times and completed in midFebruary 1995. Bone marrow done in September 1994 was Introduction normal with normal metaphases (46,XX) on cytogenetic analysis. A repeat bone marrow in August 1995 showed no eviMyelodysplastic syndromes (MDS) are a heterogeneous group dence of APL. Cytogenetic studies were: 46,XX,−7, +marker of stem cell disorders characterized by refractory cytopenias, in 10 metaphases; 45,XX,−7 in seven metaphases; 46,XX in frequent cytogenetic abnormalities, and the risk of transformthree metaphases. Repeat marrow studies in October 1995 ation to acute myelogenous leukemia (AML). An increasing again showed only 2.5% blasts, 1.5% promyelocytes with proportion of these patients have had previous exposure to mild erythroid hyperplasia and mild megakaryocytopenia. chemotherapeutic agents, classically alkylating agents, 1 but Cytogenetic studies were: 46,XX,der(7)del(7)(p10)del(7)( also anthracyclines and epidophyllotoxins.
Introduction normal with normal metaphases (46,XX) on cytogenetic analysis. A repeat bone marrow in August 1995 showed no eviMyelodysplastic syndromes (MDS) are a heterogeneous group dence of APL. Cytogenetic studies were: 46,XX,−7, +marker of stem cell disorders characterized by refractory cytopenias, in 10 metaphases; 45,XX,−7 in seven metaphases; 46,XX in frequent cytogenetic abnormalities, and the risk of transformthree metaphases. Repeat marrow studies in October 1995 ation to acute myelogenous leukemia (AML). An increasing again showed only 2.5% blasts, 1.5% promyelocytes with proportion of these patients have had previous exposure to mild erythroid hyperplasia and mild megakaryocytopenia. chemotherapeutic agents, classically alkylating agents, 1 but Cytogenetic studies were: 46,XX,der(7)del(7)(p10)del(7)( also anthracyclines and epidophyllotoxins. 2, 3 The latter group q21.1) in seven metaphases; 45,XX,−7 in six metaphases; and tends to exhibit a myelomonocytic or monocytic morphology 46,XX in three metaphases. Hemoglobin was 10.9 g/dl; WBC (M4 or M5), a short latency period, no preceding antecedent was 2.5 × 10 3 /l with 39% segmented, 31% lymphocytes, hematologic disorder, and chromosome abnormalities 19% monocytes, and 6% immature cells; and platelets count (particularly translocations) involving chromosome 11q23, or was 88 × 10 3 /l. In January 1996 the Hb was 10.8 g/dl; WBC 21q22. They have a high response rate to induction chemo-4.1 × 10 3 /l with 25% segmented, 17% monocytes, 10% mettherapy, but eventually relapse, and have a poor long-term amyelocytes, 5% myelocytes, 2% promyelocytes and 1% prognosis.
blasts; platelet count was 67 × 10 3 /l. Marrow studies showed We report a patient with acute promyelocytic leukemia 8% blasts and 4% promyelocytes, with mild dysplastic (APL) who developed MDS shortly after completion of 18 changes in the erythroid and granulocytic series. Cytogenetic months of all-trans retinoic acid (ATRA) and chemotherapy, studies were: 46,XX,der(7)del(7)(q21.1) in eight metaphases, while the primary disease was in complete remission. and 45,XX,−7 in 12 metaphases. The patient developed refractory anemia with excess blast in transformation in July 1996, with the two cytogenetic clones in 15 and six metaphases Case report respectively; 21% blasts in the marrow; and platelet count of 32 × 10 3 /l. She achieved a complete remission with combi-A 26-year-old female was diagnosed with APL in December nation chemotherapy including fludarabine idarubicin and 1992. The peripheral white blood cell (WBC) count was 8. 4 cytosine arabinoside in August 1996, and was started on × 10 3 /l with 88% abnormal promyelocytes, and a platelet maintenance chemotherapy. count of 6 × 10 3 /l. Her prothrombin time was 13.7 s and partial thromboplastin time was 20.7 s, FSP Ͼ40 and fibrinoDiscussion gen 160 mg%. A bone marrow aspirate showed 62% abnormal promyelocytes. Cytogenetic analysis showed the classical Myelodysplastic syndrome developing in patients with APL translocation t(15;17) characteristic of APL (M3). The patient following chemotherapy is rare. Occasional patients with APL received induction therapy with ATRA at 45 mg/m 2 /day and have later developed AML, usually with a short or no preleuidarubicin 12 mg/m 2 /day intravenously (i.v.) for 4 days, and kemic phase. In one case report, AML with t(7;21) developed in a patient who had been in remission from APL for 2 years. The other possibility is that the patient has developed a ther-
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Myelodysplasia following treatment of chronic lymphocytic leukemia (CLL) with 2-chlorodeoxyadenosine (2-CdA)
Therapy-related myelodysplastic syndromes (t-MDS) and of the erythroid precursors. Karyotypic analysis revealed monosomy 7 in 20 out of 26 metaphases. acute myeloid leukemias are well documented complications
Because of a suspected immune component to the patient's of chemotherapeutic regimens. Most follow treatment with cytopenias, a splenectomy was performed. The spleen alkylating agents after a median interval of 4-5 years, and are weighed 1131 g and showed lymphoid depletion and promiassociated with prominent dysplasia and deletions of chromonent extramedullary hematopoiesis. Dysplastic features were somes 5 and 7.
1-4 A less common form associated with topoapparent in the erythroid precursors and megakaryocytes. isomerase II inhibitors has a shorter latency period, presents Scattered throughout were collections of immature granulode novo as acute myeloid leukemia without prominent dyscytic precursors. plasia, and has translocations involving chromosome band The patient's course was characterized by persistent cyto11q23. [1] [2] [3] [4] We have recently encountered a patient who penias with infectious complications; he succumbed on the developed an MDS following treatment of B chronic lympho25th day of his hospital admission. Post-mortem examination cytic leukemia (CLL) with the purine analog 2-CdA. To our revealed no evidence of residual CLL. Retrospective review of knowledge, t-MDS has not been reported in association with all previous BM biopsies prior to the current admission this agent. Although it is not possible to prove a causal link revealed no evidence of dysplasia and no ringed sideroblasts in this case, it is important that the hematology community were seen. be made aware of this potential association.
In summary, this patient developed a myelodysplastic synThe patient, aged 49, presented wih pneumonia in August drome associated with monosomy 7 less than 1. years follow-1993. History did not reveal any toxic exposure. Evaluation ing 2-CdA therapy for CLL. The question of whether these revealed a mature lymphocytosis (9.94 × 10 9 /l) with anemia were causally related is a matter for conjecture. Importantly, (hemoglobin 10.4 g/dl), thrombocytopenia (platelets the patient never received alkylating agents during his course. 100 × 10 9 /l) and splenomegaly. The bone marrow (BM) was Although the latency period in this case would be short for a infiltrated by mature-appearing lymphocytes which comprised t-MDS, intervals shorter than this have been reported. 2 Epide-75% of nucleated cells. Granulocytic and erythroid precursors miological analysis of a large cohort of patients receiving 2-and megakaryocytes were decreased in number with normal CdA will be necessary to demonstrate whether an association morphology. Flow cytometry showed CD5-positive B cells truly exists. with lambda light chain restriction. A diagnosis of Rai stage IV CLL was established, and the patient received five cycles SH Kroft 
Pure red cell aplasia caused by B19 parvovirus infection after autologous blood stem cell transplantation in a patient with chronic lymphocytic leukemia
Transient aplastic crisis can follow parvovirus B19 (parvovirus) and IgG antibodies, however, could not be detected in the patient's sera. In May 1996, the bone marrow finding was infection in patients with an underlying disorder that either indicative of remission of B-CLL and enhanced erythropoiesis; decreases the life span or reduces the production of erythroby PCR analysis no parvovirus DNA was now detectable. cytes. 1 Thus, parvovirus-associated pure red cell aplasia PRCA is occasionally seen in patients with B-CLL. It is (PRCA) sometimes occurs in patients with chronic autoassumed that the acquired form of PRCA is caused by reduced immune hemolytic anemia, sickle cell anemia and hereditary proliferation of erythroid progenitor or precursor cells, and red cell membrane disorders, as well as in those with iron that in B-CLL patients, the pathogenetic mechanism is usually deficiency anemia and thalassemia. 2 The occurrence of parvoimmunological. 4 In our patient parvovirus infection was an virus infections in patients with B cell chronic lymphocytic apparent explanation for the aplastic crisis. PRCA resolved leukemia (B-CLL)-related PRCA is unknown. We describe here either spontaneously or with erythropoietin stimulation within a patient with B-CLL who developed aplastic crisis presum-4 weeks, and there have been no signs of relapse during a ably due to parvovirus infection after treatment with fludarafollow-up of 2 months. High-dose intravenous immunoglobbine and subsequent autologous peripheral blood progenitor ulin preparations have been given to immunodeficient cell transplantation.
patients to treat persistent parvovirus infection. 1, 4 This thera-A 50-year-old man was diagnosed to have stage C B-CLL peutic approach was not considered in our patient since parin 1991. He was periodically treated with chlorambucil and vovirus DNA was rapidly cleared from his bone marrow. This prednisone. In spring 1995 his disease was reactivated, and patient is among those few so far reported cases whose B-CLL at this time it proliferated very rapidly. He was treated with has been treated with fludarabine and subsequent autologous five cycles of fludarabine with a poor response. After two peripheral blood progenitor cell transplantation. An interestadditional cycles of cladribine he achieved a complete ing question remains whether these new treatment modalities remission without excess of CD19/CD5 + cells. In this increase the risk of PRCA in patients with B-CLL. On the basis remission state, blood progenitor cells were collected, and an of this case, we advocate searching for evidence of parvovirus autologous blood stem cell transplantation was performed in infection in patients with B-CLL who develop PRCA. January 1996. The conditioning regimen included high-dose cyclophosphamide and total body irradiation. Engraftment M Itälä polymerase chain reaction (PCR) 3 in the bone marrow aspir-
Translocation (3;21)(q26;q22) in de novo acute myelogenous leukemia
The translocation (3;21) is usually found in chronic myelogenanalyze the signals of AML1, and fusion genes of the major and minor bcr/abl by fluorescence in situ hybridization (FISH). ous leukemia in blast crisis (CML-BC) or therapy-related acute myelogenous leukemia/myelodysplasia (t-AML/t-MDS). [1] [2] [3] However, the major and minor bcr/abl fusion genes were not detected by FISH in peripheral blood cells. Moreover, 18% This abnormality is always accompanied by either a standard or variant 9;22 translocation in CML-BC, 1,2 and the characterof peripheral leukocytes had three signals of AML1 by FISH (Figure 1a ). Chromosome analysis of bone marrow cells istics of CML-BC with or without t(3;21) are generally well known. However, the clinical features of t-AML/t-MDS showed 46, XY, t(3;21)(q26;q22), inv (12) (p13;q24) in 19 of 21 metaphases. The Philadelphia chromosome was not found. patients with t(3;21) have not been detailed. We report a rare case of de novo AML with t(3;21)(q26;q22), whose clinical Reverse transcription-polymerase chain reaction (RT-PCR) analysis for mRNA of the major and minor bcr/abl did not features are similar to CML-BC.
A 37-year-old man was admitted to our hospital with a high detect these chimeric transcripts. Acute myelogenous leukemia, M2, was diagnosed. fever. The WBC count was 63 600/l, with 49.6% blasts and 1.6% basophils. The hemoglobin was 7.3 g/dl, reticulocyte
We attempted to detect the chimeric transcripts of AML1/EAP, AML1/MDS1, and AML1/EVI1. RNA was prepared count 15.9 × 10 4 /l, nucleated RBC count 30/100 WBC; the platelet count was 0.5 × 10 4 /l. In the bone marrow aspirate, from peripheral mononuclear cells (density Ͻ1.077 g/ml) at his first admission, using RNAZOL B (Cinna/Biotecx; Houston, the all nucleated cells (ANC) count was 24.0 × 10 4 /l, and the blasts were 77.2% of ANC with positive peroxidase activity.
TX, USA) according to the manufacturer's protocol. RT-PCR was performed by the Perkin-Elmer Gene Amp RNA PCR Kit Auer rods were found in some blasts. The neutrophil alkaline phosphatase score and rate were 27 and 12%, respectively. and the Perkin-Elmer Gene Amp PCR System 9600-R (Norwalk, CT, USA). The sequences of primers 1 (upstream The biochemical examination showed a high level of LDH; 2431 IU/l and the spleen was palpable 13 cm below the costal primer) and 2-4 (downstream primers) are as follows: 1 (AML1 primer) ACAAACCCACCGCAAGT; 2 (EAP primer) arch in the midclavicular line, which suggested the clinical characteristics of CML. Heparinized peripheral blood was ACTTTGATCCTTTCTTG; 3 (MDS1 primer) CATCTGCAT-CTGGCATT; and 4 (EVI1 primer) GCAGCGATATTGCCGTT, used by the Special Reference Laboratory (Tokyo, Japan) to and are as described. 4 RT-PCR was performed as previously described. 5 The RT-PCR product with AML1/EAP primers was twice a day, days 1 to 4) and mitoxantrone (8 mg/m 2 , days 5 and 6), which did not lead to a complete remission. The peripheral blood showed reticulocytosis and nucleated RBC, and the bone marrow showed erythroid hyperplasia with 27.6% blasts. A second induction therapy, daunorubicin (45 mg/m 2 , days 3 to 5) and cytosine arabinoside (1.4 g/m 2 twice a day, days 3 to 7), combined with granulocyte colony-stimulating factor (300 g, days 1 to 7) and cyclosporin A (8 mg/kg, days 2 to 5), also failed to improve hematological findings and secondary myelofibrosis occurred. Thereafter, he received peripheral blood stem cells from his HLA-identical sister. However, he died on day 13 from hepatic veno-occlusive disease.
AML1 is rearranged in the leukemic cells of t(8;21) AML patients. 6 Analysis of the cDNA structure has led to the identification of the fusion of AML1 with MTG8 (ETO) on chromosome 8. 7 In the 3;21 translocation, the AML1/EVI1 fusion gene is often found in CML-BC and t-AML/t-MDS, 4,8 and the AML1/EAP fusion gene is also found in some t-AML/t-MDS patients.
9,10 The t(3;21)(q26;q22) is thought to play an important role in the progression of CML to blast crisis. 8 Therefore, in this case, AML was caused by the AML1/EAP fusion gene, which caused unique clinical features. The clinical characteristics of splenomegaly, low neutrophil alkaline phosphatase, high LDH, and secondary myelofibrosis resemble those of CML. It is not known whether the clinical features of most t-AML/t-MDS patients with t(3;21)(q26;q22) are similar to those of CML-BC. Rubin et al 3 have reported We detected the chimeric transcript of AML1/EAP in this case. However, the band was larger than that reported by Nucifora et al. 4 It may be that this PCR product had an unknown sequence inserted between the AML1 and EAP sequences. Accrual and study of similar patients with this novel transcript may shed light on this particular aspect of leu-
